Drug intelligence / Profile preview

B-3E07

Development stage: Phase 1
Lead developer: Yifan Pharmaceutical

Overview

B-3E07 is a biologic drug candidate currently in preclinical development by Yifan Pharmaceutical for the treatment of osteoporosis. As an early-stage asset in Yifan's innovative biologics portfolio, specific details regarding its molecular target, mechanism of action, and specific biologic modality (such as monoclonal antibody or recombinant protein) have not yet been publicly disclosed. The program aims to provide a new therapeutic option for managing bone density and strength in patients with osteoporosis.

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on B-3E07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-3E07.

Explore the full profile